Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 10:15:1490129.
doi: 10.3389/fimmu.2024.1490129. eCollection 2024.

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Dianying Zhang #  1 , Jingjing Zhao #  2   3 , Yujing Zhang  4 , Hongfei Jiang  5 , Dan Liu  1
Affiliations

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Dianying Zhang et al. Front Immunol. .
No abstract available

Keywords: biomarker-guided therapy; cancer therapy; combination therapies; immune checkpoint inhibitors; immune-related adverse events (irAEs).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol. (2022) 13:963533. - PMC - PubMed
    1. Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. (2023) 13:1077468. doi: 10.3389/fphar.2022.1077468 - DOI - PMC - PubMed
    1. Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol. (2022) 12:958720. doi: 10.3389/fonc.2022.958720 - DOI - PMC - PubMed
    1. Papouin B, Mussini C, De Martin E, Guettier C. Effets secondaires digestifs et hépatiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors: anti-CTLA-4 et anti-PD-1/PD-L1): aspects anatomocliniques. Annales Pathologie. (2018) 38:338–51. doi: 10.1016/j.annpat.2018.07.005 - DOI - PubMed
    1. Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N, et al. Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database. Front Pharmacol. (2022) 13:803706. doi: 10.3389/fphar.2022.803706 - DOI - PMC - PubMed

LinkOut - more resources